Lead Oligonucleotide Development Scientist (PMO/ASO)

Dyne Therapeutics; Waltham (MA); Presencial; USD 159.000 - 200.000; Jornada completa

Ventajas ofrecidas por este puesto de trabajo

Onsite role

Descripción de la vacante

Dyne Therapeutics in Waltham, MA is seeking a Principal Scientist of Oligonucleotide Development to lead the synthesis strategy for PMO and modified ASO payloads, coordinating internal efforts and external CDMOs toward IND-enabling studies.

The role drives scalable, cost-effective manufacturing processes and serves as the technical lead for external partnerships while steering preclinical assets and CMC strategies within a matrixed organization.

Formación

• Strong track record in PMO and modified ASO synthesis and purification.
• Experience with CDMOs and tech transfer.
• Experience in preclinical to IND-enabling development including CMC.
• Experience in regulatory filings (IND/IMPD) documentation.

Responsabilidades

• Drive technical leadership and strategy for PMO and modified ASO payload development.
• Oversee process development, analytical strategy, and impurity control for clinical supply.
• Coordinate with external CDMOs and manage tech transfer activities.
• Support regulatory submissions and prepare Module 3 documentation.
• Review cGMP documentation, Master Batch Records, and campaign summaries.

Conocimientos

Oligonucleotide process chemistry

CDMO management

Regulatory strategy

Analytical development

Cross-functional leadership

Strategic problem solving

Educación

Bachelor’s degree in Biochemistry, Chemical Engineering, Chemistry, or Pharmaceutical Sciences

Descripción del empleo

Dyne Therapeutics in Waltham, MA is seeking a Principal Scientist of Oligonucleotide Development to lead the synthesis strategy for PMO and modified ASO payloads, coordinating internal efforts and external CDMOs toward IND-enabling studies.

The role drives scalable, cost-effective manufacturing processes and serves as the technical lead for external partnerships while steering preclinical assets and CMC strategies within a matrixed organization.